Latest Rome process Stories
SAN DIEGO, June 3 /PRNewswire/ -- Tioga Pharmaceuticals, Inc. announced today that the company has dosed its first subject in a Phase 3 clinical trial to evaluate asimadoline for the treatment of patients with diarrhea-predominant irritable bowel syndrome (DIBS).
Results confirm earlier Cedars-Sinai studies showing effectiveness of rifaximin against chronic IBS.
Functional GI Disorders Are Common, Comprise about 40 percent of GI Diagnoses BETHESDA, Md., April 6 /PRNewswire-USNewswire/ -- New clinical algorithms will give physicians a practical, efficient and cost-effective aid to diagnose the frequent gastrointestinal symptoms that patients commonly bring to their primary care doctors and gastroenterologists--symptoms of functional GI disorders that are often difficult to diagnose. Developed by the Rome Foundation and published in the April issue of...
WALTHAM, Mass., April 5 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that thought leaders believe Prometheus's Lotronex has efficacy advantages over current and emerging therapies for non-constipation predominant irritable bowel syndrome but side effects associated with the drug limit its use.
Nurses participating in shift work, especially those working rotating shifts, face a significantly increased risk of developing Irritable Bowel Syndrome (IBS) and abdominal pain compared to those working a standard day-time schedule.
Irritable bowel syndrome (IBS) is a common gastrointestinal functional disorder that can greatly affect the patient's well being.
IBS remains a common intestinal disorder causing significant discomfort and poor quality of life in patients who have the diagnosis. TCAs have been shown to improve abdominal pain in patients with IBS
Although visceral hypersensitivity is considered a hallmark feature of IBS, conflicting evidence exists regarding somatic hypersensitivity in this patient population.
MEBANE, N.C., June 1 /PRNewswire/ -- Behavioral Health Associates of NC, Inc. announces the release for sale of the iPhone symptom tracker application for Irritable Bowel Syndrome.
-- Data Presented Today at DDW Demonstrate Linaclotide Provided Early Onset of Abdominal Pain Relief and Improved Bowel Habits -- CAMBRIDGE, Mass. and NEW YORK, May 31, 2009 /PRNewswire-FirstCall/ -- Ironwood Pharmaceuticals, Inc. and Forest Laboratories, Inc.
- A member of the swell-mob; a genteelly clad pickpocket. Sometimes mobsman.